Journal
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA
Volume 28, Issue 8, Pages 498-503Publisher
EDICIONES DOYMA S A
DOI: 10.1016/j.eimc.2009.07.015
Keywords
Staphylococcus aureus; Daptomycin; Endocarditis
Categories
Funding
- Cubist Pharmaceuticals
Ask authors/readers for more resources
Introduction: In a recent randomized trial of Staphylococcus aureus bacteremia and native valve endocarditis, daptomycin was found not inferior to standard therapy. We summarized findings in the subgroup of patients with endocarditis according to the Duke criteria. Methods: Patients were randomly assigned to receive daptomycin 6 mg/kg/day or standard therapy (vancomycin 1 g every 12 h or antistaphylococcal penicillin 2 g every 4 h, both with gentamicin 1 mg/kg every 8 h for the first 4 days). The primary end point was success in the modified intent-to-treat population 6 weeks after the end of therapy. Results: Fifty-three patients were included: 35 with right-sided endocarditis (RIE) and 18 with left-sided endocarditis (LIE). The success rates in patients with RIE were similar between daptomycin and the comparator (42% vs 44%). Patients with RIE with septic pulmonary infarcts responded similarly to treatment with daptomycin and standard therapy (60% vs 67%). In the LIE population, treatment success rates were poor in both arms (11% vs 22%). Conclusion: Daptomycin is an efficacious and well-tolerated alternative to standard therapy in the treatment of RIE. Patients with LIE had a poor outcome regardless of the treatment received. Daptomycin is also effective in treating endocarditis with septic pulmonary infarcts. (C) 2009 Elsevier Espana, S.L. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available